Inversago Pharma (Canada) announced that it has secured a $7 million series A financing to pursue its development plan and advance its CB1 platform as a potent treatment for targeted diseases.
This funding will enable the company to advance its peripherally-restricted CB1 inverse agonist/antagonist program into clinical trials.
Inversago is developing new generations of CB1 receptor blockers. First generation CB1 blockers were previously in development by other major pharmaceutical companies for a range of metabolic conditions and showed striking efficacy in clinical trials. However, these third-party compounds were centrally-acting and led to psychiatric adverse events which caused the termination of all first generation CB1 inverse agonist programs.
Inversago’s technology, based on the work by CB1 world expert George Kunos at the National Institute of Health (NIH/NIAAA), has demonstrated that in preclinical models, peripherally restricted CB1 blockade provides a clear therapeutic potential to treat conditions like obesity, NASH, liver fibrosis and diabetes, without causing the CNS or behavioural effects associated with the earlier generations of CB1 blockers.
Also, research in the past several years has shown that pancreatic β-cells express CB1 receptors and that blocking these receptors positively influences insulin secretory function and, importantly, also promotes β-cell proliferation and survival under diabetic conditions.
A specialized, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome (PWS), type 1 diabetes (T1D), obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH).